To include your compound in the COVID-19 Resource Center, submit it here.

The universe in an exosome

Versatope is banking on E. coli exosomes and M2 for a universal flu vaccine

Versatope Therapeutics Inc. is using exosomes from commensal E. coli as the backbone of a universal influenza vaccine that should be cheaper and easier to manufacture than other vesicle-based vaccines.

The company’s technology was developed by scientific co-founder David Putnam, a professor of biomedical engineering at Cornell University. Putnam and colleagues engineered non-pathogenic strains of commensal E. coli that produce low levels

Read the full 615 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers